Darzalex (daratumumab) vs Talvey (talquetamab-tgvs)
Darzalex (daratumumab) vs Talvey (talquetamab-tgvs)
Darzalex (daratumumab) is a CD38-directed cytolytic antibody used in the treatment of multiple myeloma, which works by targeting and binding to the CD38 protein found on the surface of myeloma cells, leading to their destruction. Talquetamab-tgvs (brand name Talzenna), on the other hand, is a bispecific antibody that targets both GPRC5D, a protein on myeloma cells, and CD3 on T-cells, thereby facilitating an immune response against the cancer cells. When deciding between the two, a patient should consider factors such as the specific indications of each drug, their mechanism of action, the patient's previous treatments and responses, potential side effects, and the advice of their healthcare provider, as both medicines are used for different stages and settings of multiple myeloma treatment.
Difference between Darzalex and Talvey
Metric | Darzalex (daratumumab) | Talvey (talquetamab-tgvs) |
---|---|---|
Generic name | Daratumumab | Talquetamab-tgvs |
Indications | Multiple myeloma | Relapsed or refractory multiple myeloma |
Mechanism of action | CD38-directed cytolytic antibody | G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody |
Brand names | Darzalex | Talvey |
Administrative route | Intravenous | Subcutaneous |
Side effects | Infusion reactions, fatigue, nausea, back pain, fever, cough | Cytokine release syndrome, skin reactions, dysgeusia, fatigue, pyrexia |
Contraindications | Hypersensitivity to daratumumab or its excipients | Hypersensitivity to talquetamab-tgvs or its excipients |
Drug class | Monoclonal antibody | Bispecific antibody |
Manufacturer | Janssen Biotech, Inc. | Janssen Biotech, Inc. |
Efficacy
Darzalex (daratumumab) Efficacy in Multiple Myeloma
Darzalex (daratumumab) is a monoclonal antibody that targets CD38, a surface protein widely expressed on multiple myeloma cells. It is approved for the treatment of multiple myeloma in patients who have received at least one prior therapy. Clinical trials have demonstrated that Darzalex, when used in combination with other standard therapies, can significantly improve outcomes in multiple myeloma patients. For instance, in the CASTOR study, adding daratumumab to bortezomib and dexamethasone nearly doubled progression-free survival (PFS) compared to the control group. Similarly, the POLLUX study showed that daratumumab combined with lenalidomide and dexamethasone resulted in a significant reduction in the risk of disease progression or death.
Further, Darzalex has shown efficacy as a monotherapy in heavily pre-treated multiple myeloma patients. In a pivotal phase 2 study, daratumumab monotherapy resulted in a meaningful overall response rate (ORR) in patients who had received a median of five prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The safety profile of Darzalex is also well-characterized, with infusion-related reactions being the most commonly reported adverse event.
Talquetamab-tgvs (Talzenna) Efficacy in Multiple Myeloma
Talquetamab-tgvs (Talzenna) is a bispecific antibody that binds to both GPRC5D, a protein expressed on the surface of multiple myeloma cells, and CD3 on T cells, thereby redirecting T cells to kill the myeloma cells. As of the knowledge cutoff date, talquetamab-tgvs is an investigational agent and has not yet been approved for use. However, early clinical trial results have shown promise for its use in treating multiple myeloma. Data from phase 1 studies suggest that talquetamab-tgvs can induce responses in a proportion of patients with relapsed or refractory multiple myeloma, even in those who have been heavily pre-treated with existing therapies.
While comprehensive efficacy data for talquetamab-tgvs is still being gathered, initial findings indicate that it has the potential to be an important addition to the multiple myeloma treatment landscape. The safety profile and optimal dosing regimen are subjects of ongoing research. As with many investigational drugs, further clinical trials are necessary to fully understand the efficacy and safety of talquetamab-tgvs in multiple myeloma patients.
Regulatory Agency Approvals
Darzalex
Talvey
Access Darzalex or Talvey today
If Darzalex or Talvey are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us